Biosimilars have been around for years, but the biopharma industry – as well as the healthcare community – has been slow to embrace them. Today, however, the competition is really beginning to heat up, with a rising tide of new biosimilar approvals coming from both established companies and new players, including companies in emerging markets, such as India. A number of companies have found success in the biosimilars market, having experience in biological drug manufacture, financial muscle, and brand recognition. You will be facing steep competition while trying to enter Western markets. One key to success is to consider facility size, particulary before you have something on the market.
Learn more about a more modular and flexible approach: